INSUBCONTINENT EXCLUSIVE:
503.80 crore for the September quarter.
The company had reported Rs 284.90 croe profit in the yer-ago quarter.
Consolidated net sales for
the quarter rose 7 per cent to Rs 3,797 crore compared with Rs 3,546 crore in the same quarter last year.
Co-chairman and CEO, GV Prasad
said, "I am encouraged with our performance and progress in the second quarter
Our continuous focus on execution, operational efficiency and cost optimisation are showing results
Looking ahead, our priority will be to resolve pending regulatory issues, and continue to work on execution and cost structures that will
enable affordable medicines for more patients."
Gross margin for the quarter rose 55 per cent in September quarter cmopared with a rise of
55.7 per cent in June quarter and 53.33 per cent in the year-ago quarter.
"The sequential decline wasattributable to the contribution from
ExSuboxone marginal improvement in margin led by higher contribution from branded generics markets, favorable forex partially offset by
price erosion in some of our key molecules," the company said in a BSE filing.
The company will hold earnings call at 6 pm.
